Scripps Health
Trial Pipeline
Diagnostic Refinement and Educational Approaches in Managing Bone Marrow Transplantation
NCT06590285
Non-Invasive Detection of Right-to-Left Cardiac Shunts
NCT07420400
TNBC Gut Microbiota During Neoadjuvant Treatment
NCT06610097
Closed Loop Spinal Cord Stimulation for Complex Regional Pain Syndrome
NCT06421350
Sleepless at Scripps: An Inpatient White Noise Study
NCT05475262
Evaluating Infrasonic Hemodynography
NCT04636892
Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia
NCT05388123
SLeep and OPioid UsE in Patients Undergoing Total Knee Arthroplasty
NCT04247646
Survey on Precision Medicine and Digital Health
NCT03543631
Adverse Events Related to Low Dose Atropine
NCT05683535
Oral vs Intravenous Acetominophen for Postoperative Pain in Minimally Invasive Gynecologic Surgery
NCT03391284
Genotype Information and Functional Testing Study
NCT00992420
The MagnaSafe Registry: Determining the Risks of Magnetic Resonance Imaging (MRI) in the Presence of Pacemakers and Implantable Cardioverter Defibrillators (ICDs)
NCT00907361
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
What the Pipeline for Scripps Health Shows
According to the ClinicalTrials.gov registry, Scripps Health is linked to 44 US clinical trials across every stage of research activity. Of those, 37 studies are currently recruiting — about 84% of the sponsor's indexed portfolio — and 5 are already marked complete, representing roughly 11% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Scripps Health reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 1 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Scripps Health is Coronary Artery Disease with 2 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.